0000000001033942

AUTHOR

Federica De Cicco

showing 3 related works from this author

A rare rarity: neuroendocrine tumor of the esophagus

2019

Abstract Esophageal Neuroendocrine tumors (NETs) are rare, aggressive and lacking specific symptoms. This causes a diagnostic delay, worsening the prognosis. Numerous cases are reported in literature, without a consensus on the management. Our aim was to clarify epidemiology, clinical presentation, diagnostic, therapeutic management of esophageal NETs. Extensive literature search identified a total of 226 articles. One hundred twenty-five articles (n = 1676) met the inclusion criteria, showing that: the incidence of esophageal NET varies geographically; men (60–70 years) are more affected; smoking and alcohol abuse are the major risk factors; dysphagia, weight loss, appetite loss are the mo…

0301 basic medicinemedicine.medical_specialtyCarcinoid tumorsesophageal neoplasmsNeuroendocrine tumorsSmall-cell carcinomaGastroenterology03 medical and health sciences0302 clinical medicinegastroenteropancreatic NETInternal medicineEpidemiologymedicinerisk factorsesophageal NEC; gastroenteropancreatic NET; large cell esophageal NEN; MANEC; small cell carcinoma; delayed diagnosis; esophageal neoplasms; humans; neuroendocrine tumors; prognosis; rare diseases; risk factorsEsophagusStage (cooking)esophageal NECdelayed diagnosishumanssmall cell carcinomabusiness.industryLarge cellMANECrare diseasesHematologymedicine.diseaseDysphagia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesislarge cell esophageal NENprognosismedicine.symptomneuroendocrine tumorsbusiness
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

2020

AbstractGut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microb…

Endocrinology Diabetes and MetabolismTumor microenvironment.BiologyGut floraNeuroendocrine tumorsmedicine.disease_causedigestive systemArticle03 medical and health sciences0302 clinical medicineEndocrinologyImmune systemNeuroendocrine tumorGastro-medicineHumansCytokine030304 developmental biologyGastrointestinal NeoplasmsInflammation0303 health sciencesTumor microenvironmentMicrobiotadigestive oral and skin physiologymedicine.diseasebiology.organism_classificationCytokines; Inflammation; Microbiota; Neuroendocrine tumors; Tumor microenvironmentGastrointestinal MicrobiomeTumor microenvironment030220 oncology & carcinogenesisImmunologyDysbiosisCytokinesNeuroendocrine tumorsCarcinogenesisDysbiosisDrug metabolism
researchProduct